Provided by Tiger Trade Technology Pte. Ltd.

Gilead Sciences

146.30
+0.71000.49%
Post-market: 146.300.00000.00%19:53 EDT
Volume:4.54M
Turnover:660.59M
Market Cap:181.51B
PE:-55.95
High:146.35
Open:144.00
Low:142.94
Close:145.59
52wk High:157.29
52wk Low:108.46
Shares:1.24B
Float Shares:1.24B
Volume Ratio:0.88
T/O Rate:0.37%
Dividend:3.22
Dividend Rate:2.20%
EPS(TTM):-2.6150
EPS(LYR):6.78
ROE:-20.68%
ROA:14.09%
PB:15.34
PE(LYR):21.58

Loading ...

Gilead Sciences Inc Stock (GILD) Moved Down by 3.26% on Sep 8: Drivers Behind the Movement

TradingKey
·
Sep 09

Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines

THOMSON REUTERS
·
Sep 09

Movement Alert|Gilead Sciences Falls 3.18% in Regular Trading, Trading at $148.555

Market Focus
·
Sep 08

Movement Alert|Gilead Sciences Falls 3.47% in Pre-Market Trading, Trading at $146.39

Market Focus
·
Sep 08

Mirum Pharmaceuticals Names Rob Myers Chief Medical Officer Effective Sept. 21, 2026

Reuters
·
Sep 08

Gilead Sciences (GILD) Receives a Buy from Bernstein

TIPRANKS
·
Sep 08

Gilead Sciences Inc. Stock Underperforms Thursday When Compared to Competitors Despite Daily Gains

Dow Jones
·
Sep 04

Gilead’s Arcus-Backed Cancer Trial Reaches Completion, Setting Up a Key Immuno-Oncology Catalyst

TIPRANKS
·
Sep 04

Eikon Therapeutics Names Ching-Pin Chang as Chief Scientific Officer

Reuters
·
Sep 03

Gilead CEO Daniel O'Day Disposes of USD 2.23 Million in Common Shares

Reuters
·
Sep 03

Is Gilead Sciences (GILD) Fully Valued On Its New HIV And Cancer Drug Approvals?

Simply Wall St.
·
Sep 02

Gilead Sciences Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 02

Moderna Inc. Stock Advances 9.9%, Outperforms Peers

Dow Jones
·
Sep 02

Global Pharma Companies That Have Publicly Announced Trump Drug Pricing Agreements

Reuters
·
Sep 01

Gilead (GILD) Stock Stays Cheap After A 143% Five Year Run

Simply Wall St.
·
Aug 30

Gilead Sciences Inc. Stock Underperforms Friday When Compared to Competitors

Dow Jones
·
Aug 29

Gilead Sciences Stock (GILD) Slips 2% Despite FDA Approval of Bixlenvo

TIPRANKS
·
Aug 29

Gilead Breaks Ground on Foster City Biologics Facility in $32 Billion US Investment Push

Reuters
·
Aug 28

Gilead Sciences Director Anthony Welters Disposes of USD 2.64 Million in Common Shares

Reuters
·
Aug 28

Gilead’s Bixlenvo approved by FDA for virologically suppressed adults with HIV

TIPRANKS
·
Aug 28